Navigation Links
Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Date:12/15/2009

NEW YORK, Dec. 15 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

http://www.reportlinker.com/p0168100/The-Future-of-Autoimmune-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html

Summary

The author has released its latest research "The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis" The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global autoimmune diseases therapeutics market. The report analyzes the markets for autoimmune disease therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

Scope

The scope of this report includes:

- Annualized market data for the autoimmune diseases therapeutics market from 2000 to 2008, forecast forward to 2015

- Analysis of the leading therapeutic segments including rheumatoid arthritis, multiple sclerosis, systemic lupus, erythematosus, crohn's disease and ulcerative colitis

- Analysis of the autoimmune diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan

- Market characterization of the autoimmune diseases therapeutics market including market size, annual cost of therapy, sales volume and treatment usage patterns

- Key drivers and barriers that have a significant impact on the market

- Coverage of pipeline molecules in various phases of drug development

- Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Novartis AG, Sanofi-aventis, Amgen Inc, AstraZeneca, Merck & Co, Pfizer Inc, Celgene Corporation, Bristol-Myers Squibb and Eli Lilly

- Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global autoimmune diseases therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Align product portfolio to the markets with high growth potential

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety

- Develop key strategic initiatives by understanding key focus areas of leading companies

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction To the Global Autoimmune Disease Therapeutics Market

2.1 Introduction

2.2 GBI Research Report Guidance

3 Global Autoimmune Disease Therapeutics Market: Market Characterization

3.1 Market Overview

3.2 Market Forecasts

3.3 Branded Versus Generics

3.4 Market Share by Disease Sectors

3.5 Average Cost of Therapy

3.6 Volume

3.7 Usage Patterns

3.7.1 Diseased Population

3.7.2 Treatment Seeking Population

3.7.3 Diagnosis Population

3.7.4 Prescription Population

3.7.5 Therapeutics Usage Patterns

3.8 Geographical Distribution

3.9 Drivers and Restraints

3.9.1 Market Drivers

3.9.2 Market Restraints

3.10 Unmet Needs

3.11 Key Market Trends

3.11.1 Growing Patient Population and Medical Proclivity for Long Term Treatments

3.11.2 High levels of Unmet Need

3.11.3 Increasing Acceptance of Biologics for Autoimmune Disease Treatment

3.11.4 Increase in Drug Label Extension Over the Forecast Period

3.11.5 Increase in Strategic Consolidation Within the Autoimmune Disease Therapeutics Market

4 Global Rheumatoid Arthritis Therapeutics Market

4.1 Market Overview

4.2 Market Forecasts

4.3 Average Cost of Therapy

4.4 Volume

4.5 Usage Patterns

4.5.1 Diseased Population

4.5.2 Treatment Seeking Population

4.5.3 Diagnosis Population

4.5.4 Prescription Population

4.5.5 Therapeutic Usage Patterns

4.6 Product Analysis

4.6.1 Orencia

4.6.2 Voltaren/Cataflam

4.6.3 Enbrel

4.6.4 Remicade

4.6.5 Humira

4.6.6 Rituxan

4.6.7 Prograf

4.6.8 Rheumatrex

4.6.9 Celebrex

4.6.10 Arava

4.7 Drug Pipeline Analysis

5 Global Systemic Lupus Erythematosus Therapeutics Market

5.1 Market Overview

5.2 Market Forecasts

5.3 Average Cost of Therapy

5.4 Volume

5.5 Usage Patterns

5.5.1 Diseased Population

5.5.2 Treatment Seeking Population

5.5.3 Diagnosis Population

5.5.4 Prescription Population

5.5.5 Therapeutic Usage Patterns

5.6 Product Analysis

5.6.1 CellCept

5.6.2 Medrol/Depo-Medrol

5.6.3 Plaquenil

5.6.4 Imuran

5.6.5 Azasan

5.6.6 Cyclophosphamide

5.6.7 Rituximab

5.7 Drug Pipeline Analysis

6 Global Multiple Sclerosis Therapeutics Market

6.1 Market Overview

6.2 Market Forecasts

6.3 Average Cost of Therapy

6.4 Volume

6.5 Usage Patterns

6.5.1 Diseased Population

6.5.2 Treatment Seeking Population

6.5.3 Diagnosis Population

6.5.4 Prescription Population

6.5.5 Therapeutic Usage Patterns

6.6 Product Analysis

6.6.1 Avonex

6.6.2 Acthar

6.6.3 Betaferon/Betaseron

6.6.4 Copaxone

6.6.5 Rebif

6.6.6 Tysabri

6.7 Drug Pipeline Analysis

7 Global Psoriasis Therapeutics Market

7.1 Market Overview

7.2 Market Forecasts

7.3 Average Cost of Therapy

7.4 Volume

7.5 Usage Patterns

7.5.1 Diseased Population

7.5.2 Treatment Seeking Population

7.5.3 Diagnosis Population

7.5.4 Prescription Population

7.5.5 Therapeutic Usage Patterns

7.6 Product Analysis

7.6.1 Amevive

7.6.2 Dovonex

7.6.3 Enbrel

7.6.4 Fumaderm

7.6.5 Humira

7.6.6 Neoral

7.6.7 Raptiva

7.6.8 Remicade

7.6.9 Tazorac

7.7 Drug Pipeline Analysis

8 Global Crohn's Disease Therapeutics Market

8.1 Market Overview

8.2 Market Forecasts

8.3 Average Cost of Therapy

8.4 Volume

8.5 Usage Patterns

8.5.1 Diseased Population

8.5.2 Treatment Seeking Population

8.5.3 Diagnosis Population

8.5.4 Prescription Population

8.5.5 Therapeutics Usage Patterns

8.6 Product Analysis

8.6.1 Asacol

8.6.2 Cimzia

8.6.3 Entocort EC

8.6.4 Humira

8.6.5 Remicade

8.7 Drug Pipeline Analysis

9 Global Ulcerative Colitis Therapeutics Market

9.1 Market Overview

9.2 Market Forecasts

9.3 Average Cost of Therapy

9.4 Volume

9.5 Usage Patterns

9.5.1 Diseased Population

9.5.2 Treatment Seeking Population

9.5.3 Diagnosis Population

9.5.4 Prescription Population

9.5.5 Therapeutic Usage Patterns

9.6 Product Analysis

9.6.1 Asacol

9.6.2 Apriso

9.7 Drug Pipeline Analysis

10 Global Autoimmune Disease Therapeutics Market: The US Market

10.1 Market Overview

10.2 Market Forecasts

10.3 Average Cost of Therapy

10.4 Volume

10.5 Usage Patterns

10.5.1 Diseased Population

10.5.2 Treatment Seeking Population

10.5.3 Diagnosis Population

10.5.4 Prescription Population

10.5.5 Therapeutic Usage Patterns

11 Global Autoimmune Disease Therapeutics Market: The European Market

11.1 Market Overview

11.2 Market Forecasts

11.3 Average Cost of Therapy

11.4 Volume

11.5 Usage Patterns

11.5.1 Diseased Population

11.5.2 Treatment Seeking Population

11.5.3 Diagnosis Population

11.5.4 Prescription Population

11.5.5 Therapeutic Usage Patterns

12 Global Autoimmune Disease Therapeutics Market: The Japanese Market

12.1 Market Overview

12.2 Market Forecasts

12.3 Average Cost of Therapy

12.4 Volume

12.5 Usage Patterns

12.5.1 Diseased Population

12.5.2 Treatment Seeking Population

12.5.3 Diagnosis Population

12.5.4 Prescription Population

12.5.5 Therapeutic Usage Patterns

13 Global Autoimmune Disease Therapeutics Market: Competitive Landscape

13.1 Overview

13.2 Competitive Profiling

13.2.1 Amgen

13.2.2 Bristol-Myers Squibb

13.2.3 Novartis

13.2.4 Pfizer

13.2.5 Bayer AG

13.2.6 Biogen Idec.

13.2.7 Roche

13.2.8 Sanofi-aventis

13.2.9 Johnson & Johnson

13.2.10 Shire Pharmaceuticals

13.2.11 UCB Pharma

13.2.12 Salix Pharmaceuticals

13.2.13 Abbott Pharmaceuticals

13.2.14 Takeda Pharmaceutical

13.2.15 Teva Pharmaceuticals

13.2.16 Santen Pharma

13.2.17 Warner Chilcott

13.2.18 Roxane labs

13.2.19 Questcor Pharmaceutical

13.2.20 Procter & Gamble Pharmaceuticals

13.2.21 Merck Serono

13.2.22 Forest Laboratories

13.2.23 Allergan Pharmaceuticals

13.2.24 Astellas Pharma Inc.

13.2.25 King Pharmaceuticals

13.2.26 Prometheus Labs

14 Global Autoimmune Disease Therapeutics Market: Strategic Consolidations

14.1 Mergers and Acquisitions (M&A)

14.1.1 Cephalon, Inc. Acquired Arana Therapeutics Limited

14.1.2 Johnson & Johnson Acquired Elan Corporation plc

14.1.3 Bayer Healthcare acquired Genzyme Corp.

14.1.4 Paladin Labs Inc. acquired ViRexx Medical Corp.

14.2 Licensing Agreements

14.2.1 Overview

14.2.2 Discovery and Preclinical

14.2.3 Phase I

14.2.4 Phase II

14.2.5 Phase III

14.2.6 Approved

15 Appendix

15.1 Market Definitions

15.2 Abbreviations

15.3 Research Methodology

15.3.1 Coverage

15.3.2 Secondary Research

15.3.3 Primary Research

15.3.4 Forecasts

15.3.5 Expert Panel Validation

15.4 Contact Us

15.5 Disclaimer

1.1 List of Tables

Table 1: Autoimmune Disease Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2008

Table 2: Autoimmune Disease Therapeutics Market, Global, Revenue Forecasts ($mn), 2008-2015

Table 3: Autoimmune Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2008

Table 4: Autoimmune Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015

Table 5: Autoimmune Disease Therapeutics Market, Global, Volume, 2000-2008

Table 6: Autoimmune Disease Therapeutics Market, Global, Volume, 2008-2015

Table 7: Autoimmune Disease Therapeutics Market, Global, Diseased Population, 2000-2008

Table 8: Autoimmune Disease Therapeutics Market, Global, Diseased Population, 2008-2015

Table 9: Autoimmune Disease Therapeutics Market, Global, Treatment Seeking Population, 2000-2008

Table 10: Autoimmune Disease Therapeutics Market, Global, Treatment Seeking Population, 2008-2015

Table 11: Autoimmune Disease Therapeutics Market, Global, Diagnosis Population, 2000-2008

Table 12: Autoimmune Disease Therapeutics Market, Global, Diagnosis Population, 2008-2015

Table 13: Autoimmune Disease Therapeutics Market, Global, Prescription Population, 2000-2008

Table 14: Autoimmune Disease Therapeutics Market, Global, Prescription Population, 2008-2015

Table 15: Autoimmune Disease Therapeutics Market, Global, Therapeutic Usage Patterns, 2000-2008

Table 16: Autoimmune Disease Therapeutics Market, Global, Therapeutic Usage Patterns, 2008-2015

Table 17: Autoimmune Disease Therapeutics Market, Global, Market Drivers, 2008

Table 18: Autoimmune Disease Therapeutics Market, Global, Market Restraints, 2008

Table 19: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2008

Table 20: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecast ($mn), 2008-2015

Table 21: Rheumatoid Arthritis Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2008

Table 22: Rheumatoid Arthritis Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015

Table 23: Rheumatoid Arthritis Therapeutics Markets, Global, Volume, 2000-2008

Table 24: Rheumatoid Arthritis Therapeutics Market, Global, Volume, 2008-2015

Table 25: Rheumatoid Arthritis Therapeutics Market, Global, Diseased Population, 2000-2008

Table 26: Rheumatoid Arthritis Therapeutics Market, Global, Diseased Population, 2008-2015

Table 27: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Seeking Population, 2000-2008

Table 28: Rheumatoid Arthritis Therapeutics Market, Global, Treatment Seeking Population, 2008-2015

Table 29: Rheumatoid Arthritis Therapeutics Market, Global, Diagnosis Population, 2000-2008

Table 30: Rheumatoid Arthritis Therapeutics Market, Global, Diagnosis Population, 2008-2015

Table 31: Rheumatoid Arthritis Therapeutics Market, Global, Prescription Population, 2000-2008

Table 32: Rheumatoid Arthritis Therapeutics Market, Global, Prescription Population, 2008-2015

Table 33: Rheumatoid Arthritis Therapeutics Market, Global, Therapeutic Usage Patterns, 2000-2008

Table 34: Rheumatoid Arthritis Therapeutics Market, Global, Therapeutic Usage Patterns, 2008-2015

Table 35: Rheumatoid Arthritis Therapeutics Market, Global, Major Manufacturers and Drugs, 2008

Table 36: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2008

Table 37: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($mn), 2008-2015

Table 38: Systemic Lupus Erythematosus Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2008

Table 39: Systemic Lupus Erythematosus Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015

Table 40: Systemic Lupus Erythematosus Therapeutics Market, Global, Volume, 2000-2008

Table 41: Systemic Lupus Erythematosus Therapeutics Market, Global, Volume, 2008-2015

Table 42: Systemic Lupus Erythematosus Therapeutics Market, Global, Diseased Population, 2000-2008

Table 43: Systemic Lupus Erythematosus Therapeutics Market, Global, Diseased Population, 2008-2015

Table 44: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Seeking Population, 2000-2008

Table 45: Systemic Lupus Erythematosus Therapeutics Market, Global, Treatment Seeking Population, 2008-2015

Table 46: Systemic Lupus Erythematosus Therapeutics Market, Global, Diagnosis Population, 2000-2008

Table 47: Systemic Lupus Erythematosus Therapeutics Market, Global, Diagnosis Population, 2008-2015

Table 48: Systemic Lupus Erythematosus Therapeutics Market, Global, Prescription Population, 2000-2008

Table 49: Systemic Lupus Erythematosus Therapeutics Market, Global, Prescription Population, 2008-2015

Table 50: Systemic Lupus Erythematosus Therapeutics Market, Global, Therapeutic Usage Patterns, 2000-2008

Table 51: Systemic Lupus Erythematosus Therapeutics Market, Global, Therapeutics Usage Patterns, 2008-2015

Table 52: Rheumatoid Arthritis Therapeutics Market, Global, Major Manufacturers and Drugs, 2008

Table 53: Multiple Sclerosis Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2008

Table 54: Multiple Sclerosis Therapeutics Market, Global, Revenue Forecasts ($mn), 2008-2015

Table 55: Multiple Sclerosis Therapeutics Market, Global, Average Cost of Therapy, 2000-2008

Table 56: Multiple Sclerosis Therapeutics Market, Global, Average Cost of Therapy, 2008-2015

Table 57: Multiple Sclerosis Therapeutics Market, Global, Volume, 2000-2008

Table 58: Multiple Sclerosis Therapeutics Market, Global, Volume, 2008-2015

Table 59: Multiple Sclerosis Therapeutics Market, Global, Diseased Population, 2000-2008

Table 60: Multiple Sclerosis Therapeutics Market, Global, Diseased Population, 2008-2015

Table 61: Multiple Sclerosis Therapeutics Market, Global, Volume, 2000-2008

Table 62: Multiple Sclerosis Therapeutics Market, Global, Volume, 2008-2015

Table 63: Multiple Sclerosis Therapeutics Market, Global, Diagnosis Population, 2000-2008

Table 64: Multiple Sclerosis Therapeutics Market, Global, Diagnosis Population, 2008-2015

Table 65: Multiple Sclerosis Therapeutics Market, Global, Prescription Population, 2000-2008

Table 66: Multiple Sclerosis Therapeutics Market, Global, Prescription Population, 2008-2015

Table 67: Multiple Sclerosis Therapeutics Market, Global, Therapeutics Usage Patterns, 2000-2008

Table 68: Multiple Sclerosis Therapeutics Market, Global, Therapeutics Usage Patterns, 2008-2015

Table 69: Multiple Sclerosis Therapeutics Market, Global, Major Manufacturers and Drugs, 2008

Table 70: Psoriasis Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2008

Table 71: Psoriasis Therapeutics Market, Global, Revenue Forecasts ($mn), 2008-2015

Table 72: Psoriasis Therapeutics Market, Global, Average Cost of Therapy, 2000-2008

Table 73: Psoriasis Therapeutics Market, Global, Average Cost of Therapy, 2008-2015

Table 74: Psoriasis Therapeutics Market, Global, Volume, 2000-2008

Table 75: Psoriasis Therapeutics Market, Global, Volume, 2008-2015

Table 76: Psoriasis Therapeutics Market, Global, Diseased Population, 2000-2008

Table 77: Psoriasis Therapeutics Market, Global, Diseased Population, 2008-2015

Table 78: Psoriasis Therapeutics Market, Global, Treatment Seeking Population, 2000-2008

Table 79: Psoriasis Therapeutics Market, Global, Treatment Seeking Population, 2008-2015

Table 80: Psoriasis Therapeutics Market, Global, Diagnosis Population, 2000-2008

Table 81: Psoriasis Therapeutics Market, Global, Diagnosis Population, 2008-2015

Table 82: Psoriasis Therapeutics Market, Global, Prescription Population, 2000-2008

Table 83: Psoriasis Therapeutics Market, Global, Prescription Population, 2008-2015

Table 84: Psoriasis Therapeutics Market, Global, Therapeutic Usage Patterns, 2000-2008

Table 85: Psoriasis Therapeutics Market, Global, Therapeutics Usage Patterns, 2008-2015

Table 86: Psoriasis Therapeutics Market, Global, Major Manufacturers and Drugs, 2008

Table 87: Crohn's Disease Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2008

Table 88: Crohn's Disease Therapeutics Market, Global, Revenue Forecasts ($mn), 2008-2015

Table 89: Crohn's Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2008

Table 90: Crohn's Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015

Table 91: Crohn's Disease Therapeutics Market, Global, Volume, 2000-2008

Table 92: Crohn's Disease Therapeutics Market, Global, Volume, 2008-2015

Table 93: Crohn's Disease Therapeutics Market, Global, Diseased Population, 2000-2008

Table 94: Crohn's Disease Therapeutics Market, Global, Diseased Population, 2008-2015

Table 95: Crohn's Disease Therapeutics Market, Global, Treatment Seeking Population, 2000-2008

Table 96: Crohn's Disease Therapeutics Market, Global, Treatment Seeking Population, 2008-2015

Table 97: Crohn's Disease Therapeutics Market, Global, Diagnosis Population, 2000-2008

Table 98: Crohn's Disease Therapeutics Market, Global, Diagnosis Population, 2008-2015

Table 99: Crohn's Disease Therapeutics Market, Global, Prescription Population, 2000-2008

Table 100: Crohn's Disease Therapeutics Market, Global, Prescription Population, 2008-2015

Table 101:Crohn's Disease Therapeutics Market, Global, Therapeutics Usage Patterns, 2000-2008

Table 102:Crohn's Disease Therapeutics Market, Global, Therapeutics Usage Patterns, 2008-2015

Table 103:Crohn's Disease Therapeutics Market, Global, Major Manufacturers and Drugs, 2008

Table 104:Ulcerative Colitis Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2008

Table 105:Ulcerative Colitis Therapeutics Market, Global, Revenue Forecasts ($mn), 2008-2015

Table 106:Ulcerative Colitis Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2008

Table 107: Ulcerative Colitis Therapeutics Market, Global, Average Cost of Therapy ($), 2008-2015

Table 108:Ulcerative Colitis Therapeutics Market, Global, Volume, 2000-2008

Table 109: Ulcerative Colitis Therapeutics Market, Global, Volume, 2008-2015

Table 110:Ulcerative Colitis Therapeutics Market, Global, Diseased Population, 2000-2008

Table 111:Ulcerative Colitis Therapeutics Market, Global, Diseased Population, 2008-2015

Table 112:Ulcerative Colitis Therapeutics Market, Global, Treatment Seeking Population, 2000-2008

Table 113:Ulcerative Colitis Therapeutics Market, Global, Treatment Seeking Population, 2008-2015

Table 114:Ulcerative Colitis Therapeutics Market, Global, Diagnosis Population, 2000-2008

Table 115:Ulcerative Colitis Therapeutics Market, Global, Diagnosis Population, 2008-2015

Table 116:Ulcerative Colitis Therapeutics Market, Global, Prescription Population, 2000-2008

Table 117:Ulcerative Colitis Therapeutics Market, Global, Prescription Population, 2008-2015

Table 118:Ulcerative Colitis Therapeutics Market, Global, Therapeutic Usage Patterns, 2000-2008

Table 119:Ulcerative Colitis Therapeutics Market, Global, Therapeutic Usage Patterns, Global, 2008-2015

Table 120:Ulcerative Colitis Therapeutics Market, Global, Major Manufacturers and Drugs, 2008

Table 121:Autoimmune Disease Therapeutics Market, US, Revenue Forecasts ($mn), 2000-2008

Table 122:Autoimmune Disease Therapeutics Market, US, Revenue Forecasts ($mn), 2008-2015

Table 123:Autoimmune Disease Therapeutics Market, US, Average Cost of Therapy ($), 2000-2008

Table 124:Autoimmune Disease Therapeutics Market, US, Average Cost of Therapy ($), 2008-2015

Table 125: Autoimmune Disease Therapeutics Market, US, Volume, 2000-2008

Table 126: Autoimmune Disease Therapeutics Market, US, Volume, 2008-2015

Table 127: Autoimmune Disease Therapeutics Market, US, Diseased Population, 2000-2008

Table 128: Autoimmune Disease Therapeutics Market, US, Diseased Population, 2008-2015

Table 129: Autoimmune Disease Therapeutics Market, US, Treatment Seeking Population, 2000-2008

Table 130: Autoimmune Disease Therapeutics Market, US, Treatment Seeking Population, 2008-2015

Table 131: Autoimmune Disease Therapeutics Market, US, Diagnosis Population, 2000-2008

Table 132: Autoimmune Disease Therapeutics Market, US, Diagnosis Population, 2008-2015

Table 133: Autoimmune Disease Therapeutics Market, US, Prescription Population, 2000-2008

Table 134: Autoimmune Disease Therapeutics Market, US, Prescription Population, 2008-2015

Table 135: Autoimmune Disease Therapeutics Market, US, Therapeutics Usage Patterns, 2000-2008

Table 136: Autoimmune Disease Therapeutics Market, US, Therapeutics Usage Patterns, 2008-2015

Table 137: Autoimmune Disease Therapeutics Market, Europe, Revenue Forecasts ($mn), 2000-2008

Table 138: Autoimmune Disease Therapeutics Market, Europe, Revenue Forecasts ($mn), 2008-2015

Table 139: Autoimmune Disease Therapeutics Market, Europe, Average Cost of Therapy ($), 2000-2008

Table 140: Autoimmune Disease Therapeutics Market, Europe, Average Cost of Therapy ($), 2008-2015

Table 141: Autoimmune Disease Therapeutics Market, Europe, Volume, 2000-2008

Table 142: Autoimmune Disease Therapeutics Market, Europe, Volume, 2008-2015

Table 143: Autoimmune Disease Therapeutics Market, Europe, Diseased Population, 2000-2008

Table 144: Autoimmune Disease Therapeutics Market, Europe, Diseased Population, 2008-2015

Table 145: Autoimmune Disease Therapeutics Market, Europe, Treatment Seeking Population, 2000-2008

Table 146: Autoimmune Disease Therapeutics Market, Europe, Treatment Seeking Population, 2008-2015

Table 147: Autoimmune Disease Therapeutics Market, Europe, Diagnosis Population, 2000-2008

Table 148: Autoimmune Disease Therapeutics Market, Europe, Diagnosis Population, 2008-2015

Table 149: Autoimmune Disease Therapeutics Market, Europe, Prescription Population, 2000-2008

Table 150: Autoimmune Disease Therapeutics Market, Europe, Prescription Population, 2008-2015

Table 151: Autoimmune Disease Therapeutics Market, Europe, Therapeutic Usage Patterns, 2000-2008

Table 152: Autoimmune Disease Therapeutics Market, Europe, Therapeutic Usage Patterns, 2008-2015

Table 153: Autoimmune Disease Therapeutics Market, Japan, Revenue Forecasts ($mn), 2000-2008

Table 154: Autoimmune Disease Therapeutics Market, Japan, Revenue Forecasts ($mn), 2000-2015

Table 155: Autoimmune Disease Therapeutics Market, Japan, Average Cost of Therapy, 2000-2008

Table 156: Autoimmune Disease Therapeutics Market, Japan, Average Cost of Therapy, 2008-2015

Table 157: Autoimmune Disease Therapeutics Market, Japan, Volume, 2000-2008

Table 158: Autoimmune Disease Therapeutics Market, Japan, Volume, 2008-2015

Table 159: Autoimmune Disease Therapeutics Market, Japan, Diseased Population, 2000-2008

Table 160: Autoimmune Disease Therapeutics Market, Japan, Diseased Population, 2008-2015

Table 161: Autoimmune Disease Therapeutics Market, Japan, Treatment Seeking Population, 2000-2008

Table 162: Autoimmune Disease Therapeutics Market, Japan, Treatment Seeking Population, 2008-2015

Table 163: Autoimmune Disease Therapeutics Market, Japan, Diagnosis Population, 2000-2008

Table 164: Autoimmune Disease Therapeutics Market, Japan, Diagnosis Population, 2008-2015

Table 165: Autoimmune Disease Therapeutics Market, Japan, Prescription Population, 2000-2008

Table 166: Autoimmune Disease Therapeutics Market, Japan, Prescription Population, 2008-2015

Table 167:Autoimmune Disease Therapeutics Market, Japan, Therapeutics Usage Patterns, 2000-2008

Table 168:Autoimmune Disease Therapeutics Market, Japan, Therapeutics Usage Patterns, 2008-2015

Table 169: Autoimmune Disease Therapeutics Market, Global, Licensing Agreements for Drugs in the Discovery and Preclinical Stages, 2008

Table 170: Autoimmune Disease Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase I Stage, 2008

Table 171: Autoimmune Disease Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase II Stage, 2008

Table 172: Autoimmune Disease Therapeutics Market, Global, Licensing Agreements for Drugs in the Phase III Stage, 2008

Table 173: Autoimmune Disease Therapeutics Market, Global, Licensing Agreements for Drugs in the Approved Stage, 2008

1.2 List of Figures

Figure 1: Global Autoimmune Disease Therapeutics Market, Global Percentage Incidence of Autoimmune Diseases by Sex, 2008

Figure 2: Autoimmune Disease Therapeutics Market, Global, Major Factors Influencing the Market, 2008

Figure 3: Autoimmune Disease Therapeutics Market, Global, Key Geographical Trends, 2008

Figure 4: Autoimmune Disease Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2015

Figure 5: Autoimmune Disease Therapeutics Market, Global, Revenue Split ($bn), 2000-2015

Figure 6: Autoimmune Therapeutics Market, Global, Market Share of Disease Sectors, 2008

Figure 7: Autoimmune Disease Therapeutics Market, Global, Comparative Assessment of Key Autoimmune Disease Sectors, 2008

Figure 8: Autoimmune Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015

Figure 9: Autoimmune Disease Therapeutics Market, Global, Volume, 2000-2015

Figure 10: Autoimmune Disease Therapeutics Market, Global, Diseased Population, 2000-2015

Figure 11: Autoimmune Disease Therapeutics Market, Global, Treatment Seeking Population, 2000-2015

Figure 12: Autoimmune Disease Therapeutics Market, Global, Diagnosis Population, 2000-2015

Figure 13: Autoimmune Disease Therapeutics Market, Global, Prescription Population, 2000-2015

Figure 14: Autoimmune Disease Therapeutics Market, Global, Therapeutics Usage Patterns, 2000-2015

Figure 15: Autoimmune Disease Therapeutics Market, Global, Geographical Distribution of Revenues ($mn), 2000-2015

Figure 16: Autoimmune Disease Therapeutics Market, Global, Market Indicators, 2008

Figure 17: Autoimmune Disease Therapeutics Market, Global, Analysis of Unmet Needs for Rheumatoid Arthritis Therapeutics, 2008

Figure 18: Autoimmune Disease Therapeutics Market, Global, Analysis of Unmet Needs for Rheumatoid Arthritis Therapeutics, 2008

Figure 19: Autoimmune Disease Therapeutics Market, Global, Analysis of Unmet Needs for SLE Therapeutics, 2008

Figure 20: Autoimmune Disease Therapeutics Market, Global, Analysis of Unmet Needs for Ulcerative Colitis Therapeutics, 2008

Figure 21: Autoimmune Disease Therapeutics Market, Global, Analysis of Unmet Needs for Crohn's Disease Therapeutics, 2008

Figure 22: Autoimmune Disease Therapeutics Market, Global, Analysis of Unmet Needs for Multiple Sclerosis Therapeutics, 2008

Figure 23: Autoimmune Disease Therapeutics Market, Global, Analysis of Unmet Needs for Psoriasis Therapeutics, 2008

Figure 24: Autoimmune Disease Therapeutics Market, Global, Correlation Between Growth in Prescription Population and Market Revenues, 2000-2015

Figure 25: Autoimmune Disease Therapeutics Market, Global, Comparative Analysis of Growth in Biologics Versus Chemotherapy, 2000-2015

Figure 26: Autoimmune Disease Therapeutics Market, Global, Assessment of Growth in Drug Label Extensions, 2000-2015

Figure 27: Autoimmune Disease Therapeutics Market, Global, Assessment of Growth in M&A and Licensing Agreements, 2008-2009

Figure 28: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2015

Figure 29: Rheumatoid Arthritis Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015

Figure 30: Rheumatoid Arthritis Therapeutics Market, Global, Volume, 2000-2015

Figure 31: Rheumatoid Arthritis Therapeutics Market, Global, Diseased Population, 2000-2015

Figure 32: Rheumatoid Arthritis Market, Global, Treatment Seeking Population, 2000-2015

Figure 33: Rheumatoid Arthritis Therapeutics Market, Global, Diagnosis Population, 2000-2008

Figure 34: Rheumatoid Arthritis Therapeutics Market, Global, Prescription Population, 2000-2015

Figure 35: Rheumatoid Arthritis Therapeutics Market, Global, Therapeutic Usage Patterns, 2000-2015

Figure 36: Rheumatoid Arthritis Therapeutics Market, Global, Market Share of Major Therapeutic Drugs, 2008

Figure 37: Rheumatoid Arthritis Therapeutics Market, Global, Revenue Forecasts of Major Drugs, 2006-2008

Figure 38: Rheumatoid Arthritis Therapeutics Market, Global, Assessment of Therapeutics Classes in Pipeline, 2008

Figure 39: Rheumatoid Arthritis Therapeutics Market, Global, Share Assessment of Molecules Under Stages of Development, 2008

Figure 40: Rheumatoid Arthritis Therapeutics Market, Global, Major Manufacturers and their Pipeline Portfolio, 2008

Figure 41: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2015

Figure 42: Systemic Lupus Erythematosus Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015

Figure 43: Systemic Lupus Erythematosus Therapeutics Market, Global, Volume, 2000-2015

Figure 44: Systemic Lupus Erythematosus Therapeutics Market, Global, Diseased Population, 2000-2015

Figure 45: Systemic Lupus Erythematosus Therapeutics Market, Global, the Treatment Seeking Population, 2000-2015

Figure 46: Systemic Lupus Erythematosus Therapeutics Market, Global, Diagnosis Population, 2000-2015

Figure 47: Systemic Lupus Erythematosus Therapeutics Market, Global, Prescription Population, 2000-2015

Figure 48: Systemic Lupus Erythematosus Therapeutics Market, Global, Therapeutics Usage Patterns, 2000-2015

Figure 49: Systemic Lupus Erythematosus Therapeutics Market, Global, Market Share of Major Therapeutics Drugs, 2008

Figure 50: Systemic Lupus Erythematosus Therapeutics Market, Global, Revenue Forecasts of Major Drugs, 2006-2008

Figure 51: Systemic Lupus Erythematosus Therapeutics Market, Global, Assessment of Therapeutics Classes in Pipeline, 2008

Figure 52: Systemic Lupus Erythematosus Therapeutics Market, Global, Share Assessment of Molecules Under Stages of Development, 2008

Figure 53: Systemic Lupus Erythematosus Therapeutics Market, Global, Major Manufacturers and their Pipeline Portfolio, 2008

Figure 54: Multiple Sclerosis Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2015

Figure 55: Multiple Sclerosis Therapeutics Market, Global, Average Cost of Therapy, 2000-2015

Figure 56: Multiple Sclerosis Therapeutics Market, Global, Volume, 2000-2015

Figure 57: Multiple Sclerosis Therapeutics Market, Global, Diseased Population, 2000-2015

Figure 58: Multiple Sclerosis Therapeutics Market, Global, Treatment Seeking Population, 2000-2015

Figure 59: Multiple Sclerosis Therapeutics Market, Global, Diagnosis Population, 2000-2015

Figure 60: Multiple Sclerosis Therapeutics Market, Global, Prescription Population, 2000-2015

Figure 61: Multiple Sclerosis Therapeutics Market, Global, Therapeutic Usage Patterns, 2000-2015

Figure 62: Multiple Sclerosis Therapeutics Market, Global, Market Share of Major Therapeutics Drugs, 2008

Figure 63: Multiple Sclerosis Therapeutics Market, Global, Revenue Forecasts of Major Drugs, 2006-2008

Figure 64: Multiple Sclerosis Therapeutics Market, Global, Assessment of Therapeutics Classes in Pipeline, 2008

Figure 65: Multiple Sclerosis Therapeutics Market, Global, Share Assessment of Molecules Under Stages of Development, 2008

Figure 66: Multiple Sclerosis Therapeutics Market, Global, Major Manufacturers and their Pipeline Portfolio, 2008

Figure 67: Psoriasis Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2015

Figure 68: Psoriasis Therapeutics Market, Global, Average Cost of Therapy, 2000-2015

Figure 69: Psoriasis Therapeutics Market, Global, Volume, 2000-2015

Figure 70: Psoriasis Therapeutics Market, Global, Diseased Population, 2000-2015

Figure 71: Psoriasis Therapeutics Market, Global, Treatment Seeking Population, 2000-2015

Figure 72: Psoriasis Therapeutics Market, Global, Diagnosis Population, 2000-2015

Figure 73: Psoriasis Therapeutics Market, Global, Prescription Population, 2000-2015

Figure 74: Psoriasis Therapeutics Market, Global, Therapeutic Usage Patterns, 2000-2015

Figure 75: Psoriasis Therapeutics Market, Global, Market Share of Major Therapeutics Drugs, 2008

Figure 76: Psoriasis Therapeutics Market, Global, Revenue Major Drugs, 2006-2008

Figure 77: Psoriasis Therapeutics Market, Global, Assessment of Therapeutics Classes in Pipeline, 2008

Figure 78: Psoriasis Therapeutics Market, Global, Share Assessment of Molecules Under Stages of Development, 2008

Figure 79: Psoriasis Therapeutics Market, Global, Major Manufacturers and their Pipeline Portfolio, 2008

Figure 80: Crohn's Disease Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2015

Figure 81: Crohn's Disease Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015

Figure 82: Crohn's Disease Therapeutics Market, Global, Volume, 2000-2015

Figure 83: Crohn's Disease Therapeutics Market, Global, Disease Population, 2000-2015

Figure 84: Crohn's Disease Therapeutics Market, Global, Treatment Seeking Population, 2000-2015

Figure 85: Crohn's Disease Therapeutics Market, Global, Diagnosis Population, 2000-2015

Figure 86: Crohn's Disease Therapeutics Market, Global, Prescription Population, 2000-2015

Figure 87: Crohn's Disease Therapeutics Market, Global, Therapeutics Usage Patterns, 2000-2015

Figure 88: Crohn's Disease Therapeutics Market, Global, Market Share of Major Therapeutic Drugs, 2008

Figure 89: Crohn's Disease Therapeutics Market, Global, Revenue Major Drugs, 2006-2008

Figure 90: Crohn's Disease Therapeutics Market, Global, Assessment of Therapeutics Classes in Pipeline, 2008

Figure 91: Crohn's Disease Therapeutics Market, Global, Share Assessment of Molecules Under Stages of Development, 2008

Figure 92: Crohn's Disease Therapeutics Market, Global, Major Manufacturers and their Pipeline Portfolio, 2008

Figure 93: Ulcerative Colitis Therapeutics Market, Global, Revenue Forecasts ($mn), 2000-2015

Figure 94: Ulcerative Colitis Therapeutics Market, Global, Average Cost of Therapy ($), 2000-2015

Figure 95: Ulcerative Colitis Therapeutics Market, Global, Volume, 2000-2015

Figure 96: Ulcerative Colitis Therapeutics Market, Global, Diseased Population, 2000-2015

Figure 97: Ulcerative Colitis Therapeutics Market, Global, Treatment Seeking Population, 2000-2015

Figure 98: Ulcerative Colitis Therapeutics Market, Global, Diagnosis Population, 2000-2015

Figure 99: Ulcerative Colitis Therapeutics Market, Global, Prescription Population, 2000-2015

Figure 100:Ulcerative Colitis Therapeutics Market, Global, Therapeutics Usage Patterns, 2000-2015

Figure 101:Ulcerative Colitis Therapeutics Market, Global, Market Share of Major Therapeutic Drugs, 2008

Figure 102:Ulcerative Colitis Therapeutics Market, Global, Revenue Major Drugs, 2006-2008

Figure 103:Ulcerative Colitis Therapeutics Market, Global, Assessment of Therapeutics Classes in Pipeline, 2008

Figure 104:Ulcerative Colitis Therapeutics Market, Global, Assessment of

To order this report:

Pharmaceutical Industry: The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

More Market Research Report


    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)-652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Reportlinker Adds Biologic Imaging Reagents: Technologies and Global Markets Report
2. Reportlinker Adds Dermatological Therapeutics: Global Markets Report
3. Reportlinker Adds Markets for Advanced Wound Care Technologies Report
4. Reportlinker Adds Antiseptics and Disinfectants Report
5. Reportlinker Adds Commercial Amino Acids Report
6. Reportlinker Adds Membrane & Separation Technology News Review, 2008 Report
7. Reportlinker Adds the Dental Market: Techniques, Equipment and Materials Report
8. Reportlinker Adds Pediatric Health Care Products and Services Report
9. Reportlinker Adds Botanical and Plant-Derived Drugs: Global Markets Report
10. Reportlinker Adds 2008/2009 Healthcare Research Review Report
11. Reportlinker Adds Therapeutics and Diagnostics for Womens Disorders Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Washington, DC (PRWEB) , ... ... ... the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to ... settings. The partnership will recruit top students from U.S. universities who will ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose ... – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose ... products, garnering increased attention from all stakeholders in the development of new chemical ...
(Date:2/12/2016)... ... 12, 2016 , ... Coco Libre, the maker of coconut water beverages with ... Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic ... The invitation-only gifting suite, held this year at the W Hollywood Hotel, has become ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... ... as a Service (WaaS), today announced the integration of Clarity Intelligence Platform (CIP) ... channel partners to offer real-time business intelligence (BI) to their small and medium ...
(Date:2/12/2016)... ... February 12, 2016 , ... AssureVest Insurance Group, a ... initiating a charity drive that will raise funds earmarked to purchase computers and software ... Elementary School. , “My school is in a low-income area and has more than ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016   National Community Pharmacists Association ... issued the following statement today in response to the ... the Centers for Medicare & Medicaid Services (CMS) and ... advocates and others: patient advocacy organizations ... reviewing the full CMS analysis. Our initial reaction is ...
(Date:2/12/2016)... 12, 2016 /PRNewswire/ - Demers Ambulances announces its first delivery in ... Okaloosa County Emergency Medical Services (EMS) consisting ... one LT2 van. Quality Emergency Vehicles in Lecanto, ... the sale.  This is the latest in Demers, ongoing expansion ... President at Demers. --> Benoit LaFortune , Executive ...
(Date:2/12/2016)... , Feb. 12, 2016  Memorial Hermann Health ... Dwight Howard to bring a one-of-a-kind experience ... . Using cutting-edge technologies such as 360-degree video and ... both virtually, then literally – giving the patients and ... and it was all caught on video . ...
Breaking Medicine Technology: